Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-12 am EDT
1450.00 GBX   +3.57%
11:13aEuropean ADRs Move Slightly Lower in Friday Trading
MT
11:01aDrugmakers' shares up after Zantac lawsuit slump
RE
10:59aPUMP / DUMP #41 : This week's gainers and losers
MS
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
1659.4(c) 1646.8(c) 1556.43184(c) 1400(c) 1450(c) Last
3 254 908 5 624 487 12 919 214 26 874 285 13 535 626 Volume
-0.46% -0.76% -5.49% -10.05% +3.57% Change
More quotes
Estimated financial data (e)
Sales 2022 29 644 M 35 938 M 35 938 M
Net income 2022 4 481 M 5 433 M 5 433 M
Net Debt 2022 15 496 M 18 786 M 18 786 M
P/E ratio 2022 13,4x
Yield 2022 4,14%
Sales 2023 30 544 M 37 028 M 37 028 M
Net income 2023 5 148 M 6 241 M 6 241 M
Net Debt 2023 11 988 M 14 533 M 14 533 M
P/E ratio 2023 11,6x
Yield 2023 3,95%
Capitalization 58 701 M 71 163 M 71 163 M
EV / Sales 2022 2,50x
EV / Sales 2023 2,31x
Nbr of Employees 90 096
Free-Float 93,6%
More Financials
Company
GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also... 
Read more
More about the company
Ratings of GSK plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GSK PLC
11:13aEuropean ADRs Move Slightly Lower in Friday Trading
MT
11:01aDrugmakers' shares up after Zantac lawsuit slump
RE
10:59aPUMP / DUMP #41 : This week's gainers and losers
MS
10:00aBiotech stocks pin bounce back hopes on M&A boost
RE
08:53aFDA and EMA have concluded there is no evidence of a causal association between ranitid..
AQ
06:25aSTATEMENT : Zantac (ranitidine) litigation - Form 6-K
PU
06:06aMARKETSCREENER'S WORLD PRESS REVIEW : August 12, 2022
MS
05:42aEUROPEAN MIDDAY BRIEFING : Shares Edge Higher as Inflation Fears Ease
DJ
05:11aNORTH AMERICAN MORNING BRIEFING : Stock Futures Rise as Debate Over Inflation's Path Conti..
DJ
04:58aFTSE 100 rises after better-than-feared GDP reading
MS
04:47aEuropean shares rise as healthcare, leisure stocks gain
RE
04:24aGSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
RE
03:30aLONDON STOCK EXCHANGE : FTSE 100 climbs on smaller-than-expected GDP contraction, GSK rebo..
RE
03:28aEuropean shares eke out gains at open as healthcare stocks rebound
RE
03:06aShares in gsk rise 4.4%, haleon up 0.5% after heavy sell-off ove…
RE
More news
News in other languages on GSK PLC
05:02pLes Bourses mondiales confortées par la confiance des ménages américains
12:45pLas acciones europeas suben gracias a las ganancias de los valores del sector sanitario..
12:13pAKTIEN EUROPA SCHLUSS : Moderate Gewinne am Ende einer guten Börsenwoche
12:04pPoint marchés-Les actions continuent de profiter du ralentissement de l'inflation
11:13aLes ADR européens évoluent en légère baisse dans la négociation de vendredi
More news
Analyst Recommendations on GSK PLC
More recommendations
Analysis
Analysis-As inflation soars, European consumer goods M&A slows
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 450,00 GBX
Average target price 2 038,46 GBX
Spread / Average Target 40,6%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-14.82%69 216
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211